Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTSR1 | P30989 | 4/20 | 0.65 |
| ▸ | NTSR2 | O95665 | 2/20 | 0.65 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 6/20 | 0.53 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.49 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | F13A1 | P00488 | 1/20 | 0.49 |
| ▸ | TGM2 | P21980 | 1/20 | 0.49 |
| ▸ | DPP3 | Q9NY33 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.47 |
| ▸ | CTSH | P09668 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15080711 | 0.95 | NTSR2 (0.58) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL12523641 | 0.94 | NTSR2 (0.62) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL38652302 | 0.85 | CXCR4 (0.59) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL31290071 | 0.84 | CXCR4 (0.61) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL31506622 | 0.84 | DPP3 (0.61) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL30735734 | 0.84 | CXCR4 (0.58) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL31005883 | 0.83 | KISS1R (0.57) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL31607206 | 0.83 | CXCR4 (0.61) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL29350708 | 0.82 | DPP3 (0.64) | NTSR1NTSR2SORT1CXCR4KISS1R | |
| SCHEMBL34470399 | 0.82 | NTSR2 (0.66) | NTSR1NTSR2SORT1CXCR4KISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130296226-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | HALIMED PHARMACEUTICALS INC (US) | 2013-11-07 | — | — | US | disclosed |
| US-8476221-B2 | Methods and compositions for the treatment of metabolic disorders | HALIMED PHARMACEUTICALS, INC. (US) | 2013-07-02 | — | — | US | disclosed |
| US-20120238490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | HALIMED PHARMACEUTICALS, INC. | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296226-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, FABP3, NTSR1 | NTSR1 3/4885NTSR2 4/4885SORT1 298/4885 |
| US-20120238490-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF METABOLIC DISORDERS | GPR119, FABP3, NTSR1 | NTSR1 3/4885NTSR2 4/4885SORT1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.